比索洛尔对冠心病合并慢性阻塞性肺疾病患者BODE指数的影响

目的评价比索洛尔对冠心病合并慢性阻塞性肺疾病（COPD）患者BODE指数的影响。方法42例冠心病合并稳定期轻、中度COPD患者，给予比索洛尔口服，起始剂量1．25mg／d，逐步增加至5mg／d。治疗开始前及治疗60d后，分别检测BODE指数（BODEindex）的四个相关参数，即第1秒用力呼气容积占预计值百分比（（FEVI％pred）、功能性呼吸困难量表评分（MMRC）、6min步行距离（6MWD）、体重指数（BMI），并计算BODE指数。结果治疗前后BODE指数及其四个相关参数分别为：FEV1％pred（68．05±7．32VS．67．38±7.13）；6MWD（322．834-65．72Vs．320．43±62．34）；MMRC（2．13±0．57VS．2．18±0．65）；BMI（20．58±3．52VS．20．26±3．07）；BODEindex（3．51±1．97vs．3．54±2．01）。（均为P〉0．05）。结论比索洛尔对冠心病合并稳定期轻、中度COPD患者的BODE指数无明显影响。

The impact of bisoprolol on BODE index in patients with coronary heart disease and concomitant chronic obstructive pulmonary disease

Objective To evaluate the effect of bisoprolol on BODE index in patients with coronary heart disease and concomitant chronic obstructive pulmonary disease(COPD).Methods Oral bisoprolol,with the initial dose of 1.25 mg/d,increased gradually to 5 mg/d,was administered to 42 cases of coronary heart disease patients complicated with stable mild to moderate COPD.Before the administration of bisoprolol and 60 days after,four relevant variables of BODE index,including FEV1% of predicted(FEV1% pred),the distance walked in 6 minutes(6MWD),score on the the MMRC dyspnea scale(MMRC)and Body mass index (BMI),were measured,and BODE index were constructed with the four variables above.Results Before and after the administration of bisoprolol,the results were:FEV1% pred(68.05±7.32 vs.67.38 ±7.13);6MWD(322.83±65.72 vs.320.43±62.34);MMRC(2.13±0.57 vs.2.18±0.65);BMI(20.58±3.52vs.20.26±3.07);BODE index(3.51±1.97 vs. 3.54±2.01).(all P>0.05).Conclusion Bisoprolol had no significant effect on BODE index in patients with coronary heart disease and concomitant stable mild to moderate COPD.